Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC
Accepted 2024-05-06 00:00:00 ET · period of report 2024-05-02 · accession 0001048477-24-000073 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-06 | 2024-04-30 | BMRN | Ajer Jeffrey Robert | EVP, Chief Commercial Off | A - Grant | $68.65 | +300 | 71.8K | +0.4% | +$20.6K | |
| 2024-05-06 | 2024-05-02 | BMRN | Ajer Jeffrey Robert | EVP, Chief Commercial Off | S - Sale | $82.91 | -5,000 | 66.8K | -7% | -$414.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-30 | A | A | 300 | $68.65 | 71,767 | D | — | — | (F1) Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2024-05-02 | S | D | 5,000 | $82.91 | 66,767 | D | — | — | (F2) Trade made pursuant to a 10b5-1 plan executed on April 13, 2023. |